CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Ddrops® products, 50,000 IU, OralWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)


Name (Synonyms) Correlation
drug1620 No interverntion Wiki 1.00
drug2664 Vitamin D3 Wiki 0.50

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D002318 Cardiovascular Diseases NIH 0.21

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0001626 Abnormality of the cardiovascular system HPO 0.21

There is one clinical trial.

Clinical Trials


1 Improving Vitamin D Status in the Management of COVID-19

A novel coronavirus disease 2019 (COVID-19) outbreak is a global dramatic pandemic that is immeasurably impacting the communities. Due to lack of data, symptomatic management is used for COVID-19 infection including oxygen therapy and mechanical ventilation for those with severe infection. Considering immunomodulatory, anti-inflammatory anti-fibrotic and anti-oxidant actions of vitamin D, it's safety and ease of administration, as well as direct effects of vitamin D on immune cell proliferation and activity, pulmonary ACE2 expression and reducing surface tension, evaluation of vitamin D supplementation as an adjuvant therapeutic intervention could be of substantial clinical and economic significance. High prevalence of vitamin D deficiency in elderly, smokers, patients with chronic diseases and excess uptake by adipose tissue in obesity make investigations of its role as a secondary therapeutic agent in COVID-19 conceivable. It should be necessary to monitor serum 25(OH)D levels in all inpatient and outpatient populations with COVID-19 to identify the importance of maintaining or promptly increasing circulating levels of 25(OH)D into the optimal range of 100-150 nmol/L. The aim of this study is to conduct a double blind, randomized, controlled three weeks clinical trial on the efficacy of vitamin D (daily low dose versus weekly high dose) in COVID-19 patients in order to determine the relationship between baseline vitamin D deficiency and clinical characteristics and to asses patients' response to vitamin D supplementation in week three and determine its association with disease progression and recovery. Subjects who are randomized to high-dose will be asked to take 50,000 IU for two times during the first week and one dose over second and third weeks to quickly raise their serum levels. Subjects in the low-dose arm will take vitamin D 1000 IU daily for three weeks.

NCT04385940 COVID-19 Dietary Supplement: Ddrops® products, 50,000 IU, Oral Dietary Supplement: Vitamin D3

Primary Outcomes

Description: Number of Participants whose symptoms recovered over three weeks

Measure: Symptoms recovery

Time: Time from onset of intervention to day 21

Secondary Outcomes

Description: Number of patients who required hospitalization

Measure: Hospitalization

Time: Between diagnosis and day 21

Description: x 109/L

Measure: Blood white blood cell count (WBC)

Time: At day 0 before starting intervention and day 21 of intervention

Description: If patients required mechanical ventilation at any time after diagnosis

Measure: Duration of mechanical ventilation

Time: Between diagnosis and day 21

Description: Length of stay in hospital (days)

Measure: Duration of hospitalization

Time: Between diagnosis and day 21

Description: Number of patients who required ICU

Measure: Intensive care unit (ICU) admission

Time: Between diagnosis and day 21

Description: Length of stay in ICU

Measure: Duration of ICU stay

Time: Between diagnosis and day 21

Description: mg/L

Measure: Blood C-reactive protein (CRP)

Time: Baseline and day 21

Description: number of lymphocytes in 1 microliter (µL) of blood

Measure: Blood Lymphocyte count

Time: Baseline and day 21

Description: ng/mL

Measure: Blood Ferritin

Time: Baseline and day 21

Description: platelets per microliter of blood

Measure: Blood platelet count

Time: Baseline and day 21

Description: pg/mL

Measure: Blood interleukin-6 (IL-6)

Time: Baseline and day 21

Description: pg/ml

Measure: Blood Tumor Necrosis Factor alpha (TNF)

Time: Baseline and day 21


No related HPO nodes (Using clinical trials)